- Home
- MAIA vs NAMM Comparison
MAIA vs NAMM Comparison
Compare MAIA & NAMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MAIA | NAMM |
|---|---|---|
| Founded | 2018 | 2024 |
| Country | United States | Cayman Islands |
| Employees | N/A | 1500 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.0M | 75.2M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | MAIA | NAMM |
|---|---|---|
| Price | $1.40 | $1.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 567.7K | 309.6K |
| Earning Date | 05-12-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $76.84 |
| Revenue Next Year | N/A | $85.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.91 |
| 52 Week High | $3.19 | $7.42 |
Technical Indicators
Market Signals| Indicator | MAIA | NAMM |
|---|---|---|
| Relative Strength Index (RSI) | 56.61 | 47.43 |
| Support Level | $1.38 | $1.32 |
| Resistance Level | $1.46 | $1.76 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 90.91 | 48.94 |
Price Performance
Historical ComparisonAbout MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
About NAMM Namib Minerals Ordinary Shares
Namib Minerals is a Pan-African multi-asset mining platform for precious and critical metals, particularly gold. The company is an established gold producer with an attractive portfolio of three gold mines in Zimbabwe, Africa. Its gold mines include How Mine, Mazowe Mine, and Redwing Mine. Its segments include the How Mine, the Mazowe Mine, and the Redwing Mine, and Others.